KR101245919B1 - 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제 - Google Patents

옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제 Download PDF

Info

Publication number
KR101245919B1
KR101245919B1 KR1020087014985A KR20087014985A KR101245919B1 KR 101245919 B1 KR101245919 B1 KR 101245919B1 KR 1020087014985 A KR1020087014985 A KR 1020087014985A KR 20087014985 A KR20087014985 A KR 20087014985A KR 101245919 B1 KR101245919 B1 KR 101245919B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
plga
microparticles
delete delete
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087014985A
Other languages
English (en)
Korean (ko)
Other versions
KR20080078000A (ko
Inventor
홀거 페터센
마르쿠스 알하임
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101245919(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20080078000A publication Critical patent/KR20080078000A/ko
Application granted granted Critical
Publication of KR101245919B1 publication Critical patent/KR101245919B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Polyesters Or Polycarbonates (AREA)
KR1020087014985A 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제 Active KR101245919B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
GB0526247.2 2005-12-22
EP06119086.4 2006-08-17
EP06119086 2006-08-17
PCT/EP2006/012313 WO2007071395A1 (en) 2005-12-22 2006-12-20 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Related Child Applications (3)

Application Number Title Priority Date Filing Date
KR1020137004518A Division KR20130024987A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020137004520A Division KR20130024988A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020137004517A Division KR101458728B1 (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제

Publications (2)

Publication Number Publication Date
KR20080078000A KR20080078000A (ko) 2008-08-26
KR101245919B1 true KR101245919B1 (ko) 2013-03-20

Family

ID=37772904

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020087014985A Active KR101245919B1 (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제
KR1020137004518A Ceased KR20130024987A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020147031146A Ceased KR20140133968A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020137004520A Ceased KR20130024988A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020137004517A Active KR101458728B1 (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020137004518A Ceased KR20130024987A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020147031146A Ceased KR20140133968A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020137004520A Ceased KR20130024988A (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR1020137004517A Active KR101458728B1 (ko) 2005-12-22 2006-12-20 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제

Country Status (22)

Country Link
US (7) US20090004283A1 (https=)
EP (3) EP1968549B1 (https=)
JP (4) JP2009520727A (https=)
KR (5) KR101245919B1 (https=)
CN (1) CN103251929A (https=)
AR (1) AR058591A1 (https=)
AU (1) AU2006328950B2 (https=)
BR (2) BR122019027412B8 (https=)
CA (1) CA2631811C (https=)
CL (1) CL2018003398A1 (https=)
EC (1) ECSP088560A (https=)
ES (2) ES2755032T3 (https=)
IL (1) IL191842A0 (https=)
IN (1) IN2015DN03936A (https=)
MA (1) MA30064B1 (https=)
NO (1) NO20082988L (https=)
PE (1) PE20071139A1 (https=)
PL (2) PL1968549T3 (https=)
PT (2) PT1968549E (https=)
RU (1) RU2464972C2 (https=)
TW (2) TWI469788B (https=)
WO (1) WO2007071395A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2164467T3 (pl) 2007-06-06 2017-07-31 Debiopharm Research & Manufacturing Sa Kompozycja farmaceutyczna o powolnym uwalnianiu wytworzona z mikrocząstek
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
JP5791278B2 (ja) * 2008-01-30 2015-10-07 ノバルティス アーゲー オクトレオチドおよび３種の線状ポリラクチド−コ−グリコリドポリマーを含む徐放性製剤
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
JP2012515791A (ja) * 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド ポリマー混成物由来の放出制御システム
US20120022137A1 (en) * 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
ES2855349T3 (es) * 2011-04-25 2021-09-23 Shan Dong Luye Pharm Co Ltd Composición de risperidona de microesferas de liberación controlada
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
DE112015005320T5 (de) * 2014-11-25 2017-08-31 Cbc Co., Ltd. Janus Nanopartikel und Verfahren zur Herstellung derselben
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
CN107405059B (zh) * 2015-06-26 2019-05-28 奥林巴斯株式会社 内窥镜电源供给系统
US12396951B2 (en) * 2016-12-27 2025-08-26 Upexmed Co. Ltd. Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
CN115551550A (zh) * 2020-05-08 2022-12-30 M技术株式会社 均匀分散有生理活性物质的微球及含有其的缓释制剂
JP6852943B1 (ja) * 2020-05-08 2021-03-31 エム・テクニック株式会社 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
KR102947972B1 (ko) 2020-05-08 2026-04-06 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
KR102464821B1 (ko) * 2022-04-13 2022-11-09 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이를 포함하는 서방형 주사제 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217893B1 (en) * 1997-04-18 2001-04-17 Pharma Biotech Sustained-release compositions and method for preparing same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0029579B1 (en) 1979-11-27 1983-02-16 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
CA2291659A1 (fr) * 1997-06-04 1998-12-10 Debio Recherche Pharmaceutique S.A. Implants pour la liberation controlee de principes pharmaceutiquement actifs et procede pour leur fabrication
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
ATE374598T1 (de) * 2002-03-15 2007-10-15 Alrise Biosystems Gmbh Mikropartikel und verfahren zur deren herstellung
ATE418323T1 (de) * 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
WO2005007122A2 (en) * 2003-07-18 2005-01-27 Oakwood Laboratories, L.L.C. Polymer stabilization
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
CN101035512B (zh) * 2004-08-12 2012-01-18 昌达生物科技公司 用于生物活性化合物可控制释放递送的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217893B1 (en) * 1997-04-18 2001-04-17 Pharma Biotech Sustained-release compositions and method for preparing same

Also Published As

Publication number Publication date
WO2007071395A1 (en) 2007-06-28
US20200206306A1 (en) 2020-07-02
US20150037420A1 (en) 2015-02-05
KR101458728B1 (ko) 2014-11-05
BRPI0620063B8 (pt) 2021-05-25
IL191842A0 (en) 2008-12-29
ECSP088560A (es) 2008-07-30
JP2015044823A (ja) 2015-03-12
PL1968549T3 (pl) 2014-10-31
AR058591A1 (es) 2008-02-13
TWI468172B (zh) 2015-01-11
JP2009520727A (ja) 2009-05-28
CN103251929A (zh) 2013-08-21
EP1968549B1 (en) 2014-05-14
IN2015DN03936A (https=) 2015-10-02
KR20130024988A (ko) 2013-03-08
NO20082988L (no) 2008-08-29
TW201424747A (zh) 2014-07-01
PE20071139A1 (es) 2007-11-16
US20090004283A1 (en) 2009-01-01
CL2018003398A1 (es) 2019-04-26
US20160120935A1 (en) 2016-05-05
EP1968549A1 (en) 2008-09-17
JP6239851B2 (ja) 2017-11-29
BRPI0620063A8 (pt) 2018-05-02
CA2631811A1 (en) 2007-06-28
JP2013177406A (ja) 2013-09-09
KR20080078000A (ko) 2008-08-26
PT2359809T (pt) 2019-11-04
US20250082718A1 (en) 2025-03-13
EP2359809A1 (en) 2011-08-24
AU2006328950B2 (en) 2010-07-29
MA30064B1 (fr) 2008-12-01
BR122019027412B8 (pt) 2021-07-27
ES2492641T3 (es) 2014-09-10
CA2631811C (en) 2017-06-20
PT1968549E (pt) 2014-08-29
BRPI0620063B1 (pt) 2020-09-08
EP3603623A1 (en) 2020-02-05
KR20140133968A (ko) 2014-11-20
RU2464972C2 (ru) 2012-10-27
KR20130024986A (ko) 2013-03-08
AU2006328950A1 (en) 2007-06-28
PL2359809T3 (pl) 2020-01-31
JP6178772B2 (ja) 2017-08-09
US20220296675A1 (en) 2022-09-22
RU2008129626A (ru) 2010-01-27
BRPI0620063A2 (pt) 2011-11-01
TWI469788B (zh) 2015-01-21
EP2359809B1 (en) 2019-08-14
TW200803921A (en) 2008-01-16
KR20130024987A (ko) 2013-03-08
JP2016216467A (ja) 2016-12-22
BR122019027412B1 (pt) 2020-12-01
US20180140662A1 (en) 2018-05-24
ES2755032T3 (es) 2020-04-21

Similar Documents

Publication Publication Date Title
KR101245919B1 (ko) 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제
US20210161806A1 (en) Octreotide Depot Formulation with Constantly High Exposure Levels
US8999390B2 (en) Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
US20100266704A1 (en) Octreotide depot formulation with constantly high exposure levels
HK1159505B (en) Octreotide depot formulation with constantly high release rates

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130712

Effective date: 20140430

Free format text: TRIAL NUMBER: 2013100001870; TRIAL DECISION FOR INVALIDATION REQUESTED 20130712

Effective date: 20140430

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20140430

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1245919

Appeal request date: 20130712

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2013100001870

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

Free format text: TRIAL NUMBER: 2014200003590; INVALIDATION

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

J301 Trial decision

Free format text: TRIAL NUMBER: 2014105000051; TRIAL DECISION FOR CORRECTION REQUESTED 20140529

Effective date: 20140620

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20140620

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 1245919

Appeal request date: 20140529

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2014105000051

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20140821

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1012459190000

Gazette reference publication date: 20130320

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

L16-X000 Post-grant third party observation filed

St.27 status event code: A-4-5-L10-L16-oth-X000

L16-X000 Post-grant third party observation filed

St.27 status event code: A-4-5-L10-L16-oth-X000

L16-X000 Post-grant third party observation filed

St.27 status event code: A-4-5-L10-L16-oth-X000

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20141202

Effective date: 20150708

Free format text: TRIAL NUMBER: 2014105000132; TRIAL DECISION FOR CORRECTION REQUESTED 20141202

Effective date: 20150708

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20150708

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 1245919

Appeal request date: 20141202

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2014105000132

L13-X000 Limitation or reissue of ip right requested

St.27 status event code: A-2-3-L10-L13-lim-X000

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20150831

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1012459190000

Gazette reference publication date: 20130320

FPAY Annual fee payment

Payment date: 20160218

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

J2X2 Appeal (before the supreme court)

Free format text: TRIAL NUMBER: 2016300000601; APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

PJ2002 Appeal before the supreme court

St.27 status event code: A-5-5-V10-V12-crt-PJ2002

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20140516

Effective date: 20160204

Free format text: TRIAL NUMBER: 2014200003590; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20140516

Effective date: 20160204

PJ1302 Judgment (patent court)

St.27 status event code: A-5-5-V10-V15-crt-PJ1302

Decision date: 20160204

Decision identifier: 2014200003590

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 20131870 (1245919)

Appeal request date: 20140516

Appellate body name: Patent Court

Decision text: 2014. 4. 30. 20131870 1245919 1, 3 5, 7 13 .

FPAY Annual fee payment

Payment date: 20170302

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180228

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

J222 Remand (patent court)

Free format text: TRIAL NUMBER: 2018240008494; REMAND (PATENT COURT) FOR INVALIDATION

PJ2202 Remand (patent court)

St.27 status event code: A-5-5-V10-V14-crt-PJ2202

Decision date: 20190927

Decision identifier: 2018240008494

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2016 601 (1245919)

Appellate body name: Patent Court

Appeal request date: 20181108

Decision authority category: National patent court

Decision text: 2014. 4. 30. 20131870 .

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2016300000601; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20160303

Effective date: 20181025

PJ1303 Judgment (supreme court)

St.27 status event code: A-5-5-V10-V15-crt-PJ1303

Decision date: 20181025

Decision authority category: Court of appeal

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2014 3590 (1245919)

Appeal request date: 20160303

Appellate body name: Supreme Court

Decision identifier: 2016300000601

FPAY Annual fee payment

Payment date: 20190227

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

J2X2 Appeal (before the supreme court)

Free format text: TRIAL NUMBER: 2019300011756; APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

PJ2002 Appeal before the supreme court

St.27 status event code: A-5-5-V10-V12-crt-PJ2002

FPAY Annual fee payment

Payment date: 20200227

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20210302

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

J222 Remand (patent court)

Free format text: TRIAL NUMBER: 2021240002663; REMAND (PATENT COURT) FOR INVALIDATION

PJ2202 Remand (patent court)

St.27 status event code: A-5-5-V10-V14-crt-PJ2202

Decision date: 20211008

Decision identifier: 2021240002663

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2019 11756 (1245919)

Appellate body name: Patent Court

Appeal request date: 20210408

Decision authority category: National patent court

Decision text: . (1. . 2. .)

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2019300011756; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20191031

Effective date: 20210408

PJ1303 Judgment (supreme court)

St.27 status event code: A-5-5-V10-V15-crt-PJ1303

Decision date: 20210408

Decision authority category: Court of appeal

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2018 8494 (1245919)

Appeal request date: 20191031

Appellate body name: Supreme Court

Decision identifier: 2019300011756

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2018240008494; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20181108

Effective date: 20190927

Free format text: TRIAL NUMBER: 2021240002663; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20210408

Effective date: 20211008

PJ1302 Judgment (patent court)

St.27 status event code: A-5-5-V10-V15-crt-PJ1302

Decision date: 20211008

Decision identifier: 2021240002663

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2019 11756 (1245919)

Appeal request date: 20210408

Appellate body name: Patent Court

Decision text: . (1. . 2. .)

Decision date: 20190927

Decision identifier: 2018240008494

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2016 601 (1245919)

Appeal request date: 20181108

Appellate body name: Patent Court

Decision text: 2014. 4. 30. 20131870 .

FPAY Annual fee payment

Payment date: 20220302

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 14